Trial NCT02993159

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

This randomized phase IIB trial studies how well tamoxifen or afimoxifene works in treating
patients with estrogen receptor positive breast cancer. Estrogen can cause the growth of
breast cancer cells. Hormone therapy using tamoxifen citrate or afimoxifene may fight breast
cancer by blocking the use of estrogen by the tumor cells.

Intervention

Afimoxifene, Laboratory Biomarker Analysis, Placebo, Tamoxifen Citrate

Condition

Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive

Investigators

Seema A. Khan, MD, Melissa L. Pilewskie, MD, Joseph M. Guenther, MD, Stephen R. Grobmyer, MD, Eun-Sil (Shelley) Hwang, MD, Amy C. Degnim, MD

See list of participating sites